Investor Centre

Pharmaceutical company Pharmaxis (ASX:PXS) has announced that the results from the recently completed Phase III trial of Bronchitol in cystic fibrosis will be presented in a late-breaking oral presentation at the 2009 European Respiratory Society congress in Vienna.

In addition, research scientists from various respiratory laboratories around the world will present data at thematic poster sessions on the use of Aridol in different settings.